Rhodium(III)-Catalyzed<i>N</i>-Nitroso-Directed CH Addition to Ethyl 2-Oxoacetate for Cycloaddition/Fragmentation Synthesis of Indazoles
作者:Jinsen Chen、Pei Chen、Chao Song、Jin Zhu
DOI:10.1002/chem.201404506
日期:2014.10.27
RhIII‐catalyzed N‐nitroso‐directed CH addition to ethyl 2‐oxoacetate allows subsequent construction of indazoles, a privileged heterocycle scaffold in synthetic chemistry, through the exploitation of reactivity between the directing group and installed group. The formal [2+2] cycloaddition/fragmentation reaction pathway identified herein, a unique reactivity pattern hitherto elusive for the N‐nitroso
[EN] COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS UTILISABLES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
申请人:SCHERING CORP
公开号:WO2010054279A1
公开(公告)日:2010-05-14
This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
[EN] NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS POUR L'INHIBITION DE FASN
申请人:FORMA THERAPEUTICS INC
公开号:WO2014164749A1
公开(公告)日:2014-10-09
The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:
本发明涉及用于抑制FASN的化合物和组合物,其合成、应用和解毒剂。本发明的一个示例化合物如下所示:
[EN] INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION<br/>[FR] COMPOSÉS À SUBSTITUANTS INDAZOLE ET AZAINDAZOLE EN TANT QUE POTENTIATEURS ALLOSTÉRIQUES DE MGLUR4, COMPOSITIONS, ET MÉTHODES DE TRAITEMENT DE DYSFONCTIONNEMENTS NEUROLOGIQUES
申请人:UNIV VANDERBILT
公开号:WO2016123629A1
公开(公告)日:2016-08-04
Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.